Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Sales | 124,019 | 116,649 | 107,846 | 113,425 | 110,631 |
| Cost of Goods | 23,574 | 17,105 | 21,519 | 22,445 | 19,263 |
| Gross Profit | 100,445 | 99,544 | 86,327 | 90,980 | 91,368 |
| Operating Expenses | 131,973 | 121,515 | 108,281 | 106,942 | 90,863 |
| Operating Income | -30,954 | -21,866 | -21,435 | -15,517 | 768 |
| Interest Expense | 1,925 | 1,947 | 1,877 | 2,168 | 2,201 |
| Other Income | 462 | -193 | 196 | -2,046 | 260 |
| Pre-tax Income | -32,417 | -24,006 | -23,116 | -19,731 | -1,173 |
| Income Tax | -411 | -34 | 3,619 | -2,078 | 3,904 |
| Net Income Continuous | -32,006 | -23,972 | -26,735 | -17,653 | -5,077 |
| Net Income | $-32,006 | $-23,972 | $-26,735 | $-17,653 | $-5,077 |
| EPS Basic Total Ops | -0.27 | -0.21 | -0.23 | -0.16 | -0.05 |
| EPS Basic Continuous Ops | -0.27 | -0.21 | -0.24 | -0.16 | -0.05 |
| EPS Diluted Total Ops | -0.27 | -0.21 | -0.23 | -0.16 | -0.05 |
| EPS Diluted Continuous Ops | -0.27 | -0.21 | -0.24 | -0.16 | -0.05 |
| EBITDA(a) | $-18,895 | $-10,416 | $-11,874 | $-5,165 | $10,272 |